GlobeNewswire BiotechnologyDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 13:00:00·⟳ 抓取 13:01:16·⚡ 决策 10-15 13:02:02 +46s·12.5 天前
argenx 宣布将于 2026 年 10 月 22 日公布三季度业绩并举行电话会，仅为日程预告、无任何业绩数据
这是一则典型的财报电话会 save-the-date 公告：只告知披露时间和拨入方式，没有任何收入、利润、指引、产品销售或临床/监管增量事实，对未来 1–10 个交易日的盈利预期无任何更新，不存在可交易的方向或 edge，应等待 10 月 22 日实际财报再研判。
📄 原文GlobeNewswire Biotechnology↗ 原文
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company,…
不做 argenx SE（ARGX.US）
本次仅为 10 月 22 日 Q3 财报电话会的日程预告（save-the-date），无任何收入、利润、指引、销售或管线增量事实，方向与 edge 均不存在；等待 10 月 22 日实际财报发布后再据真实数据研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
argenx 仅预告 10 月 22 日发布 Q3 业绩，无任何数字或业务进展，属零增量日程公告，不构成交易催化，故 AVOID。
🔎 新鲜度:最早出现 2026-10-15 · 扩散 low · price-in 风险 low ↗
主要风险
- 真正的波动事件在 2026-10-22 财报当日；本次提前一周的日程预告不提供方向，提前布局等于无信息赌博。
先例如何影响了这次决策
对本次决策的影响:确认本次不入场；将研判推迟到财报当日。
方向:无可对照先例；财报日程预告本身不产生方向性收益，故不据此做任何方向判断。
涨幅量级:无高相似对齐先例，也无需校准幅度，因为本次没有可交易催化。
形态:例行 save-the-date 公告一般无价格反应；真正的 event-study 应在 10 月 22 日实际财报发布时再做。
原文全文
展开原文 · 2,004 字
October 15, 2026
Amsterdam, the Netherlands
– argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its third quarter 2026 financial results and provide a business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at
argenx.com/investors
. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
Participants can access the conference call by dialing 800-590-8290 (United States and Canada) or 240-690-8800 (International). Country specific dial-in numbers are listed below:
Belgium 32 2290 4635
France 33 172 001717
Netherlands 31 20 795 2683
United Kingdom 44 203 393 1560
Japan 81 3 4520 9761
Switzerland 41 43 210 51 68
Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.
About argenx
argenx is the immunology innovation company, focused on turning immunology breakthroughs into medicines for patients. The company seeks novel biology wherever it emerges, co-creating with academic researchers through its Immunology Innovation Program (IIP) and investing in promising science, to develop treatments for people living with underserved diseases. By advancing molecules with the potential to reach multiple diseases and patient populations, argenx is building a world-class portfolio. This approach produced the first approved antibody fragment targeting the neonatal Fc receptor (FcRn) and today powers a growing pipeline of early and late-stage programs across several therapeutic areas. For more information, visit
www.argenx.com
and follow us on
LinkedIn
,
Instagram
,
Facebook
, and
YouTube
.
Contacts
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
Amsterdam, the Netherlands
– argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its third quarter 2026 financial results and provide a business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at
argenx.com/investors
. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
Participants can access the conference call by dialing 800-590-8290 (United States and Canada) or 240-690-8800 (International). Country specific dial-in numbers are listed below:
Belgium 32 2290 4635
France 33 172 001717
Netherlands 31 20 795 2683
United Kingdom 44 203 393 1560
Japan 81 3 4520 9761
Switzerland 41 43 210 51 68
Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.
About argenx
argenx is the immunology innovation company, focused on turning immunology breakthroughs into medicines for patients. The company seeks novel biology wherever it emerges, co-creating with academic researchers through its Immunology Innovation Program (IIP) and investing in promising science, to develop treatments for people living with underserved diseases. By advancing molecules with the potential to reach multiple diseases and patient populations, argenx is building a world-class portfolio. This approach produced the first approved antibody fragment targeting the neonatal Fc receptor (FcRn) and today powers a growing pipeline of early and late-stage programs across several therapeutic areas. For more information, visit
www.argenx.com
and follow us on
,
,
, and
YouTube
.
Contacts
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
67cce8be6a· 2026-10-15 13:02 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前